文献速递乳腺癌

HER2零表达与HER2低表达乳腺癌患者新辅助化疗后HER2状态变化的预后意义

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer.
PubMed 文献 · Eur J Cancer · 2023-06-24

该研究纳入2014至2018年间接受新辅助化疗并手术、且治疗前后HER2状态配对可得的1288例HER2低表达或零表达乳腺癌患者,评估新辅助化疗后HER2状态转变及其对临床结局的影响。结果显示HER2低表达存在时间异质性,除治疗后HER2低表达且激素受体阴性亚组外,HER2状态变化与总生存或无病生存无显著关联。

要点

  • 新辅助化疗前HER2零表达者(n=650)中,化疗后68%仍为零表达、29%转为低表达。
  • 新辅助化疗前HER2低表达者(n=638)中,32%转为零表达、59%维持低表达。
  • 雌激素受体阳性者获得HER2低表达的概率高于阴性者(比值比2.48)。

核心结论

  • 新辅助化疗后相当数量乳腺癌患者出现HER2低表达的时间异质性,除治疗后HER2低表达且激素受体阴性亚组外,HER2状态变化与临床结局无显著关联。
  • HER2低表达乳腺癌中HER2状态转变的预后意义需进一步研究。

研究设计与样本

  • 纳入2014至2018年间接受新辅助化疗并手术、且治疗前后HER2状态配对结果可得的1288例HER2低表达或零表达乳腺癌患者。

主要发现

  • 化疗前HER2零表达者(n=650)中,化疗后68%为HER2零表达、29%为HER2低表达。
  • 化疗前HER2低表达者(n=638)中,32%发生HER2变化(低表达转为零表达),59%维持HER2低表达。
  • 持续HER2低表达者与HER2低表达转为零表达者的激素受体阳性比例分别为84%和79%,高于HER2零表达转为低表达者的77%和持续HER2零表达者的56%。
  • 多因素logistic回归分析显示,雌激素受体阳性者获得HER2低表达的概率高于雌激素受体阴性者(比值比2.48)。
  • 按激素受体状态分层,除治疗后HER2低表达且激素受体阴性亚组外,有无HER2变化患者的总生存和无病生存无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • HER2低表达乳腺癌中HER2状态转变的预后意义需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The transition of human epidermal growth factor receptor 2 (HER2) status after neoadjuvant chemotherapy (NAC) in HER2-low breast cancer has not been thoroughly evaluated. Here, we evaluated the HER2 transition among HER2-zero and HER2-low breast cancer cases post-NAC and its impact on clinical outcomes. METHODS: We included 1288 patients with HER2-low or zero breast cancer who underwent NAC and surgery between 2014 and 2018 and had paired pre- and post-therapeutic HER2 status results. RESULTS: Among patients who were HER2-zero pre-NAC (n = 650), 68% and 29% were HER2-zero and HER2-low, respectively, post-NAC. Among patients who were HER2-low pre-NAC (n = 638), 32% of patients showed HER2 changes (low to zero), and 59% of patients had a constant HER2-low status post-NAC. Patients with constant HER2-low or transitions from HER2-low to zero had a higher proportion of hormone receptor positivity (84% and 79%) than those with changes from HER2-zero to low (77%) or with constant HER2-zero (56%), respectively. Multivariable logistic regression analysis revealed that patients with oestrogen receptor positivity had a higher probability of gaining HER2-low expression than those with oestrogen receptor negativity (odds ratio 2.48). No significant differences were observed in terms of overall survival or disease-free survival between patients with and without HER2-changes according to their hormone receptor status, except in the post-therapeutic HER2-low, hormone receptor-negativity subset. CONCLUSION: Temporal heterogeneity of HER2-low expression is observed in substantial numbers of post-NAC breast cancer patients. Clinical outcomes show no significant associations, except in the post-therapeutic HER2-low, hormone receptor negativity subset. The prognostic implications of HER2 transition in HER2-low breast cancer require further investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kang S, Lee SH, Lee HJ, et al. Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer. Eur J Cancer. 2023. PMID: 37473465. doi:10.1016/j.ejca.2023.112956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。